A significant regulatory filing has come to light concerning FONAR Corporation, the US-based medical imaging technology company. A Schedule 13G was submitted to the US Securities and Exchange Commission on 10 June, indicating that a hedge fund has taken a passive stake of 5% or more in the firm. Such filings are mandatory under US law when an investor acquires a substantial interest without the intention of influencing control.
FONAR, headquartered in Melville, New York, is best known for its development of magnetic resonance imaging (MRI) technology, including the upright MRI scanner. The company has a market capitalisation of roughly $150m and trades on the Nasdaq under the ticker FONR. While it has no direct UK operations, its technology is used in medical facilities globally, including some in the United Kingdom.
The 13G filing suggests the investor views FONAR as a value or growth opportunity rather than a target for activism. For UK investors with exposure to US healthcare equities through pension funds or unit trusts, this signals continued institutional confidence in the niche medical imaging sector. The filing does not disclose the exact size of the stake, but a 13G is generally used for holdings above the 5% threshold.
Analysts note that passive stakes of this nature often precede either a long-term hold or eventual exit, depending on the company's performance. FONAR has faced challenges in recent years, including regulatory scrutiny and fluctuating revenues. However, its proprietary technology and intellectual property portfolio remain assets that attract specialist investors.
For UK readers, the filing highlights the importance of monitoring cross-border institutional activity, as it can influence the performance of global healthcare funds held in ISAs or SIPPs. The filing does not constitute a recommendation to buy or sell shares in FONAR.
Source: SEC EDGAR filing, Form 13G, filed 10 June.